{
    "clinical_study": {
        "@rank": "97384", 
        "arm_group": [
            {
                "arm_group_label": "Droperidol 0.625 mg intravenously", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Droperidol 1.25 mg intravenously", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Ondansetron 8 mg intravenously", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "For many years droperidol has been used in prophylaxis and therapy of PONV. Information that\n      it can provoke disorders of cardiac ventricular rhythm reduced its popularity. However those\n      data didn't base on solid examinations confirming torsadogenic action of droperidol. It is\n      known that droperidol prolongs time of repolarisation, but there wasn't any data confirming\n      its impact on transmural dispersion of repolarisation. Only estimation both of those actions\n      in one time allows to define for sure arrhythmogenic role of droperidol.\n\n      The aim of this study was to answer the questions:\n\n      6. Does droperidol make an significant prolongation of heart repolarisation, expressed as\n      corrected QT interval?\n\n        1. Does droperidol cause increase of  transmural dispersion of repolarisation?\n\n        2. Does possible torsadogenic acting of droperidol depend on dose of drug?\n\n        3. Does ondansetron cause changes of electrical heart function, suggesting its\n           possibilities to induce TdP tachycardia?\n\n        4. What is torsadogenic potential of droperidol and ondansetron used in prophylaxis PONV\n           in people not suffering from cardiovascular diseases?"
        }, 
        "brief_title": "Droperidol and Cardiac Repolarization", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Cardiac Repolarization", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age 18-60 years\n\n          -  sex: males\n\n          -  ASA score I or II\n\n        Exclusion Criteria:\n\n          -  treatment with drugs influencing cardiac repolarization\n\n          -  coronary artery disease\n\n          -  heart insufficiency NYHA>1\n\n          -  serum electrolyte disturbances\n\n          -  hypersensitivity to droperidol and/or ondansetron"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819857", 
            "org_study_id": "RO4", 
            "secondary_id": "MUG4"
        }, 
        "intervention": [
            {
                "arm_group_label": "Droperidol 0.625 mg intravenously", 
                "description": "intravenous administration of 0.625 mg droperidol", 
                "intervention_name": "Xomolix 0.625 mg intravenously", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Droperidol 1.25 mg intravenously", 
                "description": "intravenous administration of 1.25 mg droperidol", 
                "intervention_name": "Xomolix 1.25 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ondansetron 8 mg intravenously", 
                "description": "intravenous administration of 8 mg ondansetron", 
                "intervention_name": "Zofran 8 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Droperidol", 
                "Ondansetron"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gdansk", 
                    "country": "Poland", 
                    "zip": "80-214"
                }, 
                "name": "Medical University of Gdansk"
            }
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Influence of Droperidol on Cardiac Repolarization. A Double-blind, Ondansetron-controlled Study.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Poland: Medical University of Gdansk", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in QT interval value, QTc interval value and transmural dispersion of repolarization (TDR) value", 
            "safety_issue": "Yes", 
            "time_frame": "20 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819857"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Gdansk", 
            "investigator_full_name": "Radoslaw Owczuk", 
            "investigator_title": "Principle Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Number of individuals with QTc increase by 50 ms and TDR increase by 25 ms", 
            "safety_issue": "Yes", 
            "time_frame": "20 min"
        }, 
        "source": "Medical University of Gdansk", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Gdansk", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}